Evaluation of the protective efficacy of a spatial repellent to reduce malaria incidence in children in western Kenya compared to placebo: study protocol for a cluster-randomized double-blinded control trial (the AEGIS program)

Trials. 2022 Apr 5;23(1):260. doi: 10.1186/s13063-022-06196-x.

Abstract

Background: Spatial repellents are widely used for prevention of mosquito bites and evidence is building on their public health value, but their efficacy against malaria incidence has never been evaluated in Africa. To address this knowledge gap, a trial to evaluate the efficacy of Mosquito Shield™, a spatial repellent incorporating transfluthrin, was developed for implementation in Busia County, western Kenya where long-lasting insecticidal net coverage is high and baseline malaria transmission is moderate to high year-round.

Methods: This trial is designed as a cluster-randomized, placebo-controlled, double-blinded clinical trial. Sixty clusters will be randomly assigned in a 1:1 ratio to receive spatial repellent or placebo. A total of 6120 children aged ≥6 months to 10 years of age will be randomly selected from the study clusters, enrolled into an active cohort (baseline, cohort 1, and cohort 2), and sampled monthly to determine time to first infection by smear microscopy. Each cohort following the implementation of the intervention will be split into two groups, one to estimate direct effect of the spatial repellent and the other to estimate degree of diversion of mosquitoes and malaria transmission to unprotected persons. Malaria incidence in each cohort will be estimated and compared (primary indicator) to determine benefit of using a spatial repellent in a high, year-round malaria transmission setting. Mosquitoes will be collected monthly using CDC light traps to determine if there are entomological correlates of spatial repellent efficacy that may be useful for the evaluation of new spatial repellents. Quarterly human landing catches will assess behavioral effects of the intervention.

Discussion: Findings will serve as the first cluster-randomized controlled trial powered to detect spatial repellent efficacy to reduce malaria in sub-Saharan Africa where transmission rates are high, insecticide-treated nets are widely deployed, and mosquitoes are resistant to insecticides. Results will be submitted to the World Health Organization Vector Control Advisory Group for assessment of public health value towards an endorsement to recommend inclusion of spatial repellents in malaria control programs.

Trial registration: ClinicalTrials.gov NCT04766879 . Registered February 23, 2021.

Keywords: Clinical trial; Kenya; Malaria; Spatial repellent; Transfluthrin.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Animals
  • Child
  • Humans
  • Incidence
  • Insect Repellents* / pharmacology
  • Insecticide-Treated Bednets*
  • Insecticides* / pharmacology
  • Kenya / epidemiology
  • Malaria* / epidemiology
  • Malaria* / prevention & control
  • Mosquito Control / methods
  • Randomized Controlled Trials as Topic

Substances

  • Insect Repellents
  • Insecticides

Associated data

  • ClinicalTrials.gov/NCT04766879

Grants and funding